In addition, in vivo studies have shown that inhibition of CCR5 by neutralizing antibodies or antagonists was able to retard the progression of MM, reduce osteolytic lesions, and inhibit osteoclastogenesis.179, 180. The gene discussed is CCR5; the disease is Miyoshi myopathy.